Literature DB >> 21373310

Public opinion of a stroke clinical trial using exception from informed consent.

Joshua N Goldstein, Janice A Espinola, Jonathan Fisher, Daniel J Pallin, Carlos A Camargo.   

Abstract

BACKGROUND: Acute stroke is a leading cause of morbidity and mortality. Clinical trials in stroke are challenging because victims often do not have the capacity to provide informed consent, excluding those patients most likely to benefit from the research. AIM: We evaluated patient willingness to participate in a hypothetical acute stroke trial using an exception from informed consent.
METHODS: Consecutive patients presenting to four emergency departments (EDs) underwent structured interviews regarding a hypothetical stroke trial using an exception from informed consent.
RESULTS: Of 461 (72% of eligible) participants, 55% (95% CI, 50%-59%) were willing to be enrolled in the hypothetical study without giving informed consent. After multivariable analysis, independent predictors of willingness to enroll included Catholic religion (OR 1.57, 95% CI 1.17-2.10) and belief that current therapy offers a >50% chance of full recovery (OR 1.29, 95% CI 1.05-1.57). There was no difference between the proportion willing to enroll in a cardiac arrest study vs. a stroke study (55% vs. 55%, p = 0.83)
CONCLUSIONS: Fifty-five percent of ED patients would be willing to be enrolled in a stroke trial using exception from informed consent.

Entities:  

Keywords:  Informed consent; Public opinion; Stroke

Year:  2010        PMID: 21373310      PMCID: PMC3047845          DOI: 10.1007/s12245-010-0244-2

Source DB:  PubMed          Journal:  Int J Emerg Med        ISSN: 1865-1372


Introduction

Acute stroke is a leading cause of morbidity and mortality, and few interventions have proven to improve outcome [1]. Altered mental status among stroke victims limits their ability to give informed consent, which excludes those patients most likely to benefit, skewing the study population towards those with the least severe strokes [2-4]. Therefore, some have advocated for use of an exception from the standard informed consent procedure [5, 6]. While research using this exception is allowable under federal regulations, the process is both logistically and ethically complex, and typically applied to a narrow range of diseases. When stroke survivors and caregivers are involved in stroke trial development, they have advocated for exception from consent [7]. The only study examining patient opinion of such an exception interviewed patients after their stroke had occurred, finding that 92% would be willing to participate [8]. These patients may be more aware of the long-term morbidity of stroke and the limitations of current therapies, and thus be more supportive of such research than the general public. To investigate public opinion, we interviewed a consecutive cohort of patients presenting to the emergency department (ED) for a variety of conditions [9]. Since it is impossible to discuss this issue with actual patients at the time of their stroke, we interviewed patients in the ED who would be more aware of the need for emergency evaluation and treatment, but be cognitively intact. The primary analysis examined the effect of an educational intervention on patient opinion of exception from consent in general and was published previously [9]. Here, we report a secondary analysis examining independent predictors of participants’ willingness to participate in a stroke trial in particular.

Methods

We described the study design previously, including the full questionnaire text [9]. Briefly, consecutive patients presenting to four EDs during selected 24-h periods were approached. Adults (aged >18) who were awake and responsive were eligible for enrollment. Subjects were excluded for medical instability, mental illness, intoxication, complaint of sexual assault, or if they were prisoners. The original study tested the hypothesis that an educational intervention would increase willingness to participate; subjects were randomized to receive the control survey or one with a paragraph discussing the ethical/legal requirements involved in using exception from informed consent [9]. The hypothetical stroke study is shown in Fig. 1; subjects were also asked about a hypothetical cardiac arrest study.
Fig. 1

Case scenario

Case scenario For analysis of the dichotomous variable “willing to enroll,” we collapsed answers from a 5-point Likert scale into “agree” (the responses Strongly Agree and Agree), and “do not agree” (Neutral, Disagree, and Strongly Disagree). We performed multivariable logistic regression to determine predictors of willingness to participate, with predictor variables chosen a priori based upon previously published data or suspected influence on willingness to participate in research. The model included a term for site, to account for within-ED clustering. We used Stata 9.0 (StataCorp, College Station, TX) for analysis. We also collected qualitative data using open-ended questions. The study was approved by the Institutional Review Boards of all participating sites.

Results

Of 1,080 patients presenting to the four EDs during the study period, 640 were eligible, 473 participated, and 461 (72%) answered all questions including opinion on the hypothetical stroke study (Table 1). Fifty-five percent would be willing to participate in the hypothetical stroke study, a similar proportion to that willing to participate in a hypothetical cardiac arrest study (also 55%, p = 0.83). Univariate analysis identified no significant predictors of willingness to participate in the hypothetical stroke study. Multivariate analysis identified the following independent predictors of willingness to be enrolled: male sex, Catholic religion, and belief that current therapy offers >50% chance of full recovery (Table 2).
Table 1

Demographic characteristics, by willingness to participate in a hypothetical stroke trial

DisagreeNeutralAgree P value
Overall (n = 461)34%11%55%
Age, median (IQR)46 (27–63)43 (29–59)47 (31–59)0.95
Income in $1,000 s, median (IQR)59 (47–79)59 (47–68)66 (47–79)0.74
Sex0.61
 Male (n = 214)31%9%60%
 Female (n = 241)36%12%51%
Race0.69
 White (n = 290)33%11%57%
 Black (n = 80)38%11%51%
 Other (n = 77)36%14%49%
Ethnicity0.25
 Non-Hispanic (n = 400)34%11%55%
 Hispanic (n = 18)32%12%56%
Religion0.30
 Protestant (n = 100)36%15%49%
 Catholic (n = 192)34%7%59%
 Other (n = 85)28%20%52%
 None (n = 81)37%6%57%
Strong connection to religion0.52
 No (n = 230)33%10%56%
 Yes (n = 148)34%14%51%
Education0.62
 <8th grade (n = 22)23%14%64%
 <12th grade (n = 23)30%9%61%
 High school (n = 132)34%12%54%
 Some college (n = 109)39%7%53%
 College (n = 113)34%13%53%
 Post grad. (n = 62)32%11%56%
Insurance0.84
 Private (n = 262)33%11%56%
 Medicare (n = 18)17%11%72%
 Medicaid (n = 62)35%11%53%
 None (n = 24)33%4%63%
 Other (n = 88)39%11%50%
“What do you think your chance of recovering … is, based on current therapies?”
 <5% (n = 27)41%4%55%
 5–50% (n = 94)38%10%52%
 50/50 (n = 176)33%14%53%
 >50% (n = 120)32%12%57%
 >95% (n = 30)20%7%73%0.30
Educational intervention1.0
 No (n = 233)34%11%55%
 Yes (n = 228)35%11%54%

*IQR, Interquartile range

Table 2

Multivariable analysis of clinical features associated with willingness to participate in a hypothetical stroke trial

Clinical factorOdds ratio (95% CI)
Age per decade1.0 (0.8–1.2)
Household income (per US$10,000)1.0 (0.9–1.1)
Female sex0.8 (0.7–0.9)
Race:
 WhiteReferent
 Black1.0 (0.7–1.6)
 Other0.7 (0.5–1.0)
Hispanic ethnicity1.2 (0.5–2.7)
Education:
 <8th gradeReferent
 Some high school0.9 (0.4–2.0)
 High school0.8 (0.4–1.4)
 Some college0.8 (0.4–1.3)
 College0.8 (0.4–1.7)
 Post graduate1.1 (0.4–3.0)
Religion:
 ProtestantReferent
 Catholic1.6 (1.2–2.1)
 Other1.1 (0.6–2.0)
 None1.4 (0.7–2.8)
Insurance:
 PrivateReferent
 Medicare2.1 (0.7–6.3)
 Medicaid0.9 (0.6–1.3)
 None1.3 (0.3–5.9)
Other0.7 (0.2–2.7)
Belief that current therapies offer a >50% chance of full recovery1.3 (1.1–1.6)
Educational intervention1.0 (0.7–1.6)
Demographic characteristics, by willingness to participate in a hypothetical stroke trial *IQR, Interquartile range Multivariable analysis of clinical features associated with willingness to participate in a hypothetical stroke trial Qualitative comments were provided by 37 (15%) of those who were willing to participate, and by 50 (24%) who were neutral or unwilling. The most common statement was the belief that a surrogate is always immediately available (n = 15). Other common statements included that the risks were too high (n = 10); that the research should proceed in case it might help (n = 6); and that patients should only be enrolled if it were already known that the treatment would help (n = 4).

Discussion

We found that 55% of potential subjects would be willing to participate in a stroke trial without informed consent, 11% were neutral, and 34% would refuse. Prior research has shown 34–84% of respondents to be willing to participate in other studies such as cardiac arrest without informed consent [10]. Multivariable analysis revealed that patients with a more optimistic view of the benefits of current therapies were more willing to participate. It may be that those with more positive opinions of clinical care also have more faith in the ethical management of clinical trials or a greater belief that research carries clinical benefit for the participants. We also noted an effect of sex and religious affiliation on willingness to enroll; the reason for this is unclear. Future studies will be necessary to clarify whether these relationships are artifacts of multiple hypothesis testing, or whether there is a reason that males and Catholics are more willing to participate in research without consent. Our study is limited by the fact that not all eligible subjects completed the survey; a response rate over 80% would be preferred. Also, by excluding the most severely ill patients, we may have missed those most likely to be enrolled in studies using an exception from informed consent and whose opinions are most critical. Unfortunately, while such patients who survive cognitively intact could be interviewed after their clinical course has stabilized, such interviews would select for those who benefited most from standard therapy, and decision-making at the time of the stroke may be quite different from that made long afterwards. Finally, healthy people at risk for stroke could be interviewed to avoid any biases from being in the emergency department at the time of the survey. However, patients’ opinions of research (and medical care) may be quite different when in close spatial and psychological proximity to a true medical emergency, and so such surveys may introduce a separate set of biases. These data add to the growing body of evidence for patients’ support of emergency research without informed consent. Clinical trials in stroke have not traditionally been considered candidates for exception from consent; however, our data support the concept that within the context of current federal regulations (including factors such as clinical equipoise, ethics board approval, and absence of a surrogate), the majority of patients would be willing to participate in clinical trials of novel stroke therapies without consent.
  9 in total

1.  An ethical analysis of exception from informed consent regulations.

Authors:  Marilyn C Morris
Journal:  Acad Emerg Med       Date:  2005-11       Impact factor: 3.451

2.  Stroke patients' preferences and values about emergency research.

Authors:  C E Blixen; G J Agich
Journal:  J Med Ethics       Date:  2005-10       Impact factor: 2.903

3.  What patients want: consumer involvement in the design of a randomized controlled trial of routine oxygen supplementation after acute stroke.

Authors:  Khalid Ali; Christine Roffe; Peter Crome
Journal:  Stroke       Date:  2006-02-02       Impact factor: 7.914

4.  Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Authors:  Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks
Journal:  Stroke       Date:  2007-04-12       Impact factor: 7.914

Review 5.  Conducting stroke research with an exception from the requirement for informed consent.

Authors:  Brian T Bateman; Philip M Meyers; H Christian Schumacher; Sundeep Mangla; John Pile-Spellman
Journal:  Stroke       Date:  2003-03-27       Impact factor: 7.914

6.  Impracticability of informed consent in the Registry of the Canadian Stroke Network.

Authors:  Jack V Tu; Donald J Willison; Frank L Silver; Jiming Fang; Janice A Richards; Andreas Laupacis; Moira K Kapral
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

7.  Brain lesion volume and capacity for consent in stroke trials: potential regulatory barriers to the use of surrogate markers.

Authors:  Krishna A Dani; Michael T McCormick; Keith W Muir
Journal:  Stroke       Date:  2008-06-05       Impact factor: 7.914

8.  Impact of restricting enrollment in stroke genetics research to adults able to provide informed consent.

Authors:  Donna T Chen; L Douglas Case; Thomas G Brott; Robert D Brown; Scott L Silliman; James F Meschia; Bradford B Worrall
Journal:  Stroke       Date:  2008-02-07       Impact factor: 7.914

Review 9.  Clinical research without consent in adults in the emergency setting: a review of patient and public views.

Authors:  Jan Lecouturier; Helen Rodgers; Gary A Ford; Tim Rapley; Lynne Stobbart; Stephen J Louw; Madeleine J Murtagh
Journal:  BMC Med Ethics       Date:  2008-04-29       Impact factor: 2.652

  9 in total
  9 in total

1.  Variation of community consultation and public disclosure for a pediatric multi-centered "Exception from Informed Consent" trial.

Authors:  Maija Holsti; Roger Zemek; Jill Baren; Rachel M Stanley; Prashant Mahajan; Cheryl Vance; Kathleen M Brown; Victor Gonzalez; Denise King; Kammy Jacobsen; Kate Shreve; Katrina van de Bruinhorst; Anne Marie Jones; James M Chamberlain
Journal:  Clin Trials       Date:  2014-11-04       Impact factor: 2.486

2.  Informed consent: the rate-limiting step in acute stroke trials.

Authors:  David Z Rose; Scott E Kasner
Journal:  Front Neurol       Date:  2011-10-17       Impact factor: 4.003

3.  Which factors influence the resort to surrogate consent in stroke trials, and what are the patient outcomes in this context?

Authors:  Anne-Marie Mendyk; Julien Labreuche; Hilde Henon; Marie Girot; Charlotte Cordonnier; Alain Duhamel; Didier Leys; Régis Bordet
Journal:  BMC Med Ethics       Date:  2015-04-24       Impact factor: 2.652

4.  Qualitative evaluation of a deferred consent process in paediatric emergency research: a PREDICT study.

Authors:  Jeremy Furyk; Kristin McBain-Rigg; Kerrianne Watt; Theophilus I Emeto; Richard C Franklin; Donna Franklin; Andreas Schibler; Stuart R Dalziel; Franz E Babl; Catherine Wilson; Natalie Phillips; Robin Ray
Journal:  BMJ Open       Date:  2017-11-15       Impact factor: 2.692

Review 5.  Detailed systematic analysis of recruitment strategies in randomised controlled trials in patients with an unscheduled admission to hospital.

Authors:  Ceri Rowlands; Leila Rooshenas; Katherine Fairhurst; Jonathan Rees; Carrol Gamble; Jane M Blazeby
Journal:  BMJ Open       Date:  2018-02-02       Impact factor: 2.692

6.  Effect of informed consent on patient characteristics in a stroke thrombolysis trial.

Authors:  Götz Thomalla; Florent Boutitie; Jochen B Fiebach; Claus Z Simonsen; Norbert Nighoghossian; Salvador Pedraza; Robin Lemmens; Pascal Roy; Keith W Muir; Christoph Heesen; Martin Ebinger; Ian Ford; Bastian Cheng; Tae-Hee Cho; Josep Puig; Vincent Thijs; Matthias Endres; Jens Fiehler; Christian Gerloff
Journal:  Neurology       Date:  2017-08-25       Impact factor: 9.910

7.  Deferred Consent in an Acute Stroke Trial from a Patient, Proxy, and Physician Perspective: A Cross-Sectional Survey.

Authors:  Inez Koopman; Dagmar Verbaan; W Peter Vandertop; Rieke van der Graaf; Erwin J O Kompanje; René Post; Bert A Coert; Martine C Ploem; Wouter M Sluis; Féline E V Scheijmans; Gabriel J E Rinkel; Mervyn D I Vergouwen
Journal:  Neurocrit Care       Date:  2021-10-05       Impact factor: 3.210

8.  Patient and proxies' attitudes towards deferred consent in randomised trials of acute treatment for stroke: A qualitative survey.

Authors:  Noa van den Bos; Sophie A van den Berg; Catalina Mm Caupain; Jeannette Aj Pols; Tessa van Middelaar; Vicky Chalos; Diederik Wj Dippel; Yvo Bwem Roos; Manon Kappelhof; Paul J Nederkoorn
Journal:  Eur Stroke J       Date:  2021-11-13

Review 9.  [Ethics of resuscitation and end of life decisions].

Authors:  Spyros D Mentzelopoulos; Keith Couper; Patrick Van de Voorde; Patrick Druwé; Marieke Blom; Gavin D Perkins; Ileana Lulic; Jana Djakow; Violetta Raffay; Gisela Lilja; Leo Bossaert
Journal:  Notf Rett Med       Date:  2021-06-02       Impact factor: 0.826

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.